After an FDA rejection in May, Stealth BioTherapeutics has resubmitted a new drug application for its investigational ...

Reunion Neuroscience’s psychedelic has reduced the symptoms of postpartum depression in a phase 2 study, setting up the ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 ...

Baxter’s efforts this summer to correct high-risk issues with its infusion pumps has gotten more complicated.  | Last month, ...

Genentech is continuing its summer of downsizing and cost-cutting, this time with plans to terminate a cell therapy deal ...

Gene therapy biotech Kriya Therapeutics has secured $313 million in a new series fundraise. | Gene therapy biotech Kriya ...

In an update to their guidelines for treating high blood pressure, a group of cardiovascular medical societies has included a ...

Palatin has a research program in DR, and more specifically, in diabetic macular edema (DME), a complication of DR that ...

Yet another biotech is facing a delay from the Food and Drug Administration as the agency reels from intense staffing cuts. | Yet another biotech is facing a delay from the Food and Drug ...

Omeros’ efforts to get its transplant drug to market have already suffered one FDA rejection. | Omeros’ efforts to get its ...

Jayanta Bhattacharya, M.D., Ph.D., director of the National Institutes of Health (NIH), has called on the agency’s scientific ...